Publications by authors named "Maria Learoyd"

Claim this Profile
E
Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.
David Viskochil, Mariusz Wysocki, Maria Learoyd, Peng Sun, Karen So

Neurooncol Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
Christian Rolfo, Nicolas Isambert, Antoine Italiano, L Rhoda Molife, Jan H M Schellens, Maria Learoyd

Br J Clin Pharmacol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Christian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, L Rhoda Molife, Jan H M Schellens, Maria Learoyd

Clin Pharmacokinet· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Alienor Berges

Clin Pharmacol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Alienor Berges

Clin Pharmacokinet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Peng Yuan, Jianzhong Shentu, Jianming Xu, Wendy Burke, Kate Hsu, Maria Learoyd

Cancer Chemother Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations.
Venkatesh Pilla Reddy, Khanh Bui, Graeme Scarfe, Diansong Zhou, Maria Learoyd

Clin Pharmacol Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Ruth Plummer, Henk M Verheul, Filip Y F L De Vos, Karin Leunen, L Rhoda Molife, Maria Learoyd

Adv Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel Clarke, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Maria Learoyd

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
Alex McCormick, Helen Swaisland, Venkatesh Pilla Reddy, Maria Learoyd, Graeme Scarfe

Xenobiotica· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects.
Jianguo Li, Maria Learoyd, Furong Qiu, LeiLei Zhu, Timi Edeki

Clin Drug Investig· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Maria Sunzel, Maria Learoyd, Jianguo Li, Yan Li, Ngoc Ngo

Int J Antimicrob Agents· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
David P Nicolau, Leonard Siew, Jon Armstrong, James Li, Timi Edeki, Maria Learoyd

J Antimicrob Chemother· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects.
Shampa Das, Jianguo Li, Jon Armstrong, Maria Learoyd, Timi Edeki

Pharmacol Res Perspect· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers.
Nobumitsu Tominaga, Timi Edeki, James Li, Maria Learoyd, M René Bouw

J Infect Chemother· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
Anthony W Tolcher, Khurum Khan, Michael Ong, Udai Banerji, Vassiliki Papadimitrakopoulou, Maria Learoyd

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
Roger B Cohen, Steinar Aamdal, Marta Nyakas, Maria Cavallin, Darron Green, Maria Learoyd

Eur J Cancer· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Suzanne Leijen, Patricia M M B Soetekouw, T R Jeffry Evans, Marianne Nicolson, Jan H M Schellens, Maria Learoyd

Cancer Chemother Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.
Bert H O'Neil, Laura W Goff, John Sae Wook Kauh, Jonathan R Strosberg, Tanios S Bekaii-Saab, Maria Learoyd

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis